S
Stephan Christgau
Publications - 30
Citations - 848
Stephan Christgau is an academic researcher. The author has contributed to research in topics: Strontium & Salt (chemistry). The author has an hindex of 10, co-authored 30 publications receiving 814 citations.
Papers
More filters
Journal ArticleDOI
Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen
Christian Rosenquist,C. Fledelius,Stephan Christgau,Brian Juel Pedersen,Martin Bonde,Per Qvist,Claus Christiansen +6 more
TL;DR: The Serum CrossLaps One Step ELISA was capable of detecting a highly significant (P <0.001) effect of hormone replacement therapy in a retrospective study involving 22 postmenopausal women.
Journal ArticleDOI
Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting.
TL;DR: The results of this study demonstrate that samples for sCTx should be taken in the fasting state, and show that Nasal salmon calcitonin, an antiresorptive drug used for treatment of osteoporosis, was not able to break the circadian pattern whether the treatment was administered in the morning or the evening.
Patent
Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
TL;DR: Water-soluble strontium salts have a water-solubility of from about 1 g/l to about 100 g/L at room temperature as mentioned in this paper. But they are not suitable for use in the treatment and/or prophylaxis of cartilage and bone conditions and for methods of treating such condition.
Patent
Treatments comprising strontium for rheumatic and arthritic diseases and pain
TL;DR: Improved treatments of joint diseases such as osteoarthritis and rheumatoid arthritis, and pain, wherein a strontium-containing compound is administered alone or in combination with one or more second therapeutically and/or prophylactically active substances, selected from the group consisting of bisphosphonates, glucosamine, pallitative agents, analgesic agents, disease modifying anti-rheumatic compounds (DMARDs), selective estrogen receptor modulators (SERMs), aromatase inhibitors, non-steroidal anti-inflammatory agents (NSAIDs),
Patent
Strontium combinations for prophylaxis/treatment of cartilage and/or bone conditions
TL;DR: A combination treatment, wherein a strontium-containing compound together with one or more active substances capable of reducing the incidence of bone fracture and increasing bone density and improving healing of fractured bone and/or improving bone quality are administered for use in the treatment and prophylaxis of cartilage and bone conditions, is described in this article.